JP2014532623A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532623A5
JP2014532623A5 JP2014537142A JP2014537142A JP2014532623A5 JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5 JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5
Authority
JP
Japan
Prior art keywords
composition
liposomes
lyophilization
reconstitution
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537142A
Other languages
English (en)
Japanese (ja)
Other versions
JP6133308B2 (ja
JP2014532623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/060293 external-priority patent/WO2013059133A1/en
Publication of JP2014532623A publication Critical patent/JP2014532623A/ja
Publication of JP2014532623A5 publication Critical patent/JP2014532623A5/ja
Application granted granted Critical
Publication of JP6133308B2 publication Critical patent/JP6133308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537142A 2011-10-21 2012-10-15 凍結乾燥リポソーム Active JP6133308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074348A Division JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム

Publications (3)

Publication Number Publication Date
JP2014532623A JP2014532623A (ja) 2014-12-08
JP2014532623A5 true JP2014532623A5 (https=) 2015-10-15
JP6133308B2 JP6133308B2 (ja) 2017-05-24

Family

ID=48141268

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014537142A Active JP6133308B2 (ja) 2011-10-21 2012-10-15 凍結乾燥リポソーム
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Country Status (22)

Country Link
US (5) US10028912B2 (https=)
EP (2) EP3572071A1 (https=)
JP (6) JP6133308B2 (https=)
KR (5) KR102452305B1 (https=)
CN (2) CN108853031A (https=)
AU (1) AU2012326370C9 (https=)
BR (1) BR112014009305B1 (https=)
CA (1) CA2852777C (https=)
DK (1) DK2768484T3 (https=)
ES (1) ES2750368T3 (https=)
FR (1) FR19C1063I2 (https=)
HR (1) HRP20191683T1 (https=)
HU (2) HUE045978T2 (https=)
IL (1) IL232161B (https=)
LU (1) LUC00135I2 (https=)
NL (1) NL301016I2 (https=)
NO (1) NO2019041I1 (https=)
PL (1) PL2768484T3 (https=)
PT (1) PT2768484T (https=)
RU (1) RU2648753C2 (https=)
SI (1) SI2768484T1 (https=)
WO (1) WO2013059133A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CA2958768C (en) 2014-08-28 2023-08-29 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
HUE053990T2 (hu) 2015-07-22 2021-08-30 Nitto Denko Corp Nanorészecske liofilizált formák készítményei és eljárások
US10927418B2 (en) * 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019010560A1 (en) * 2017-07-10 2019-01-17 Immmunovaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF
CN113164502A (zh) 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
JP2022542571A (ja) * 2019-07-24 2022-10-05 ザ ジェネラル ホスピタル コーポレイション カプセル化により異なる凝固点を有する物質を作製する方法
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术(石家庄)有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
WO1986003938A1 (en) 1985-01-11 1986-07-17 The Regents Of The University Of California Method for preserving liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
NZ331372A (en) 1996-02-19 2000-01-28 Nycomed Imaging As freeze-dried vesicle containing a thermally stabilized ultrasound contrast agent
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202475A3 (en) 1999-07-16 2004-06-28 Alza Corp A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
AU2002340670A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
WO2006050327A2 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2006055903A1 (en) 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
WO2011066684A1 (zh) 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi

Similar Documents

Publication Publication Date Title
JP2014532623A5 (https=)
JP2020007367A5 (https=)
JP2024045183A5 (https=)
Shao et al. Biomimetic diselenide‐bridged mesoporous organosilica nanoparticles as an X‐ray‐responsive biodegradable carrier for chemo‐immunotherapy
Wang et al. An engineered nanoplatform with tropism toward irradiated glioblastoma augments its radioimmunotherapy efficacy
HRP20191683T1 (hr) Liofilizirani liposomi
US12364664B2 (en) Lyophilized compositions comprising arsenic
Zhao et al. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review
van der Heijden et al. Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
RU2018110333A (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
NZ701915A (en) High-concentration monoclonal antibody formulations
NZ707328A (en) Virus-containing formulation and use thereof
JP2008509924A5 (https=)
JP2011251975A5 (https=)
JP2013511557A5 (https=)
WO2012107865A3 (en) Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
JP2013532729A5 (https=)
CN108495619A (zh) 棘霉素制剂及其制备方法和使用方法
JP2019521179A5 (https=)
Rampersaud et al. Hyperthermia as a treatment for bladder cancer
Joshi et al. Liposomes: a promising carrier for respiratory syncytial virus therapeutics
CN109790530A (zh) 治疗癌症的方法
AR094770A1 (es) Composición masticable para administración oral y proceso para preparar la misma
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用